English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/94773
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Preoperative serum CA 72.4 as prognostic factor of recurrence and death, especially at TNM stage II, for colorectal cancer

AuthorsAyude, Daniel; Rodríguez-Berrocal, Francisco J; Ayude, José; Blanco-Prieto, Sonia; Vázquez-Iglesias, Lorena; Vázquez-Cedeira, Marta ; Páez de la Cadena, María
Issue Date12-Nov-2013
PublisherBioMed Central
CitationBMC Cancer 13: 543 (2013)
Abstract[Background]: Nowadays, evaluation of colorectal cancer prognosis and decision-making for treatment continues to be based primarily on TNM tumour stage. Administration of adjuvant chemotherapy is especially challenging for stage II patients that can have very different disease-related outcomes. Therefore, more reliable prognostic markers need to be developed to improve the selection of stage II patients at high risk for recurrence. Our purpose is to assess the prognostic value of preoperative serum CA 72.4 to improve the risk stratification of CRC patients. [Methods]: Preoperative sera collected from 71 unselected patients between January 1994 and February 1997 was assayed for CA 72.4 and CEA levels. Patients were followed-up for at least 30 months or until relapse. Survival curves were estimated by the Kaplan-Meier method and the prognostic value was determined using Log-Rank test and Cox regression analysis. [Results]: Preoperative CA 72.4 levels above 7 U/mL correlate with a worse prognosis, with associated recurrence and death percentages exceeding the displayed by CEA. In a multivariate analysis, its combination with CEA proved the most important independent factor predicting survival. Remarkably, at stage II CA 72.4 also discriminates better than CEA those patients that will relapse or die from those with a favourable prognosis; however, CEA has not a negligible effect on survival. [Conclusions]: The most outstanding finding of the present work is the correct classification of nearly every patient with bad prognosis (relapse or death) at TNM stage II when CEA and CA 72.4 are used altogether. This could improve the decision-making involved in the treatment of stage II colon cancer. Certainly further large-scale studies must be performed to determine whether CA 72.4 can be effectively used in the clinical setting.
DescriptionThis article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License.
Publisher version (URL)http://dx.doi.org/10.1186/1471-2407-13-543
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
1471-2407-13-543.xml88,83 kBXMLView/Open
1471-2407-13-543.pdf435,25 kBAdobe PDFThumbnail
1471-2407-13-543-S1.DOCX17,93 kBMicrosoft Word XMLView/Open
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.